Overall survival with frontline vs subsequent anti-epidermal growth factor receptor therapies in unresectable,RAS/BRAF wild-type,leftsided metastatic colorectal cancer  

作　　者：Nussara Pakvisal Richard M Goldberg Chirawadee Sathitruangsak Witthaya Silaphong Satawat Faengmon Nattaya Teeyapun Chinachote Teerapakpinyo Suebpong Tanasanvimon 

机构地区：[1]Division of Medical Oncology,Department of Medicine,Faculty of Medicine,Chulalongkorn University and The King Chulalongkorn Memorial Hospital,Bangkok 10330,Thailand [2]Department of Medicine,WVU Cancer Institute,West Virginia University,Morgantown,WV 26506,United States [3]Medical Oncology Unit,Division of Internal Medicine,Faculty of Medicine,Holistic Center for Cancer Study and Care(HOCC-PSU)and Prince of Songkla University,Songkhla 90110,Thailand [4]Chulalongkorn GenePRO Center,Research Affairs,Chulalongkorn University and The King Chulalongkorn Memorial Hospital,Bangkok 10330,Thailand

出　　处：《World Journal of Clinical Oncology》2025年第3期57-67,共11页世界临床肿瘤学杂志(英文)

摘　　要：BACKGROUND The combination of anti-epidermal growth factor receptor(EGFR)therapy and chemotherapy is currently a preferred first-line treatment for patients with unre-sectable,RAS and BRAF wild-type,left-sided metastatic colorectal cancer(mCRC).Several studies have also demonstrated the benefit of anti-EGFR therapy in sub-sequent line settings for this patient population.However,direct evidence com-paring the effectiveness of frontline vs subsequent anti-EGFR therapy remains limited,leaving a crucial gap in guiding optimal treatment strategies.AIM To compare overall survival(OS)between frontline and subsequent anti-EGFR treatment in patients with unresectable,RAS and BRAF wild-type,left-sided mCRC.METHODS We retrospectively reviewed the medical records of mCRC patients treated at The King Chulalongkorn Memorial Hospital and Songklanagarind Hospital,Thailand,between January 2013 and April 2023.Patients were classified into two groups based on the sequence of their anti-EGFR treatment.The primary endpoint was OS.RESULTS Among 222 patients with a median follow-up of 29 months,no significant difference in OS was observed between the frontline and subsequent-line groups(HR 1.03,95%CI:0.73-1.46,P=0.878).The median OS was 35.53 months(95%CI:26.59-44.47)for the frontline group and 31.60 months(95%CI:27.83-35.37)for the subsequent-line group.In the subsequent-line group,71 patients(32.4%)who ultimately never received anti-EGFR therapy had a significantly worse median OS of 19.70 months(95%CI:12.87-26.53).CONCLUSION Frontline and subsequent-line anti-EGFR treatments provide comparable OS in unresectable,RAS/BRAF wild-type,left-sided mCRC patients,but early exposure is vital for those unlikely to receive subsequent therapy.

关 键 词：Metastatic colorectal cancer Anti-epidermal growth factor receptor FRONTLINE Subsequent line RAS wild-type metastatic colorectal cancer BRAF wild-type metastatic colorectal cancer Left-sided metastatic colorectal cancer Overall survival 

分 类 号：R735.34[医药卫生—肿瘤]